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Summary
The human mitochondrial deoxyribonucleotidase cat-
alyzes the dephosphorylation of thymidine and deoxy-
uridine monophosphates and participates in the regu-
lation of the dTTP pool in mitochondria. We present
seven structures of the inactive D41N variant of this en-
zyme in complex with thymidine 3-monophosphate,
thymidine 5-monophosphate, deoxyuridine 5-mono-
phosphate, uridine 5-monophosphate, deoxyguano-
sine 5-monophosphate, uridine 2-monophosphate,
and the 5-monophosphate of the nucleoside analog
3-deoxy 23-didehydrothymidine, and we draw con-
clusions about the substrate specificity based on
comparisons with enzyme activities. We show that
the enzyme’s specificity for the deoxyribo form of nu-
cleoside 5-monophosphates is due to Ile-133, Phe-
49, and Phe-102, which surround the 2 position of
the sugar and cause an energetically unfavorable
environment for the 2-hydroxyl group of ribonucleo-
side 5-monophosphates. The close binding of the
3-hydroxyl group of nucleoside 5-monophosphates
to the enzyme indicates that nucleoside analog drugs
that are substituted with a bulky group at this position
will not be good substrates for this enzyme.
Introduction
The DNA replication machinery requires a balanced
supply of the four deoxyribonucleoside triphosphates
(dNTPs) to carry out a correct DNA synthesis. The cell
uses the complex allosteric regulation of ribonucleotide
reductase and the action of various enzymes such as
nucleoside and nucleotide kinases and 5#-nucleotid-
ases to control dNTP pool sizes (Jordan and Reichard,
1998). Here, we focus on the mitochondrial deoxyribo-
nucleotidase (mdN, previously named dNT-2) (Ram-
pazzo et al., 2000a; Bianchi and Spychala, 2003), one
of seven known human 5#-nucleotidases that catalyze*Correspondence: par@dbb.su.se
4 These authors contributed equally to this work.the dephosphorylation of nucleoside monophosphates
to nucleosides and inorganic phosphate. The general
properties of 5#-nucleotidases have recently been re-
viewed (Bianchi and Spychala, 2003). Although their
substrate specificities are rather broad and partially
overlapping, individual 5#-nucleotidases show differ-
ences in substrate specificity and subcellular location.
However, with the exception of the ecto-5#-nucleotid-
ase (eN), they all have a common sequence motif,
DXDXV/T, in their active site and depend on Mg2+ for
activity, which indicates a similar catalytic mechanism
(Bianchi and Spychala, 2003).
The enzyme mdN is the only 5#-nucleotidase found
so far in mitochondria and prefers thymidine 5#-mono-
phosphate (dTMP5#), deoxyuridine 5#-monophosphate
(dUMP5#), thymidine 3#-monophosphate (dTMP3#), and
uridine 3#-monophosphate (UMP3#) as substrates (Ram-
pazzo et al., 2000a; Gallinaro et al., 2002; Mazzon et al.,
2003). The sequence of mdN is 52% identical to that
of the cytosolic deoxyribonucleotidase (cdN, previously
named dNT-1) (Rampazzo et al., 2000b; Bianchi and
Spychala, 2003), which is active with the same sub-
strates as those used by mdN but is also active with
deoxyguanosine 5#-monophosphate (dGMP5#) and de-
oxyinosine 5#monophosphate (dIMP5#) (Höglund and
Reichard, 1990; Rampazzo et al., 2000b). These two en-
zymes are the only known 5#-nucleotidases that prefer
the 2#-deoxyribo form over the ribo form of nucleoside
5#-monophosphates. The activity of mdN on non-
nucleoside phosphates has never been tested, but cdN
has been shown to be active with p-nitrophenyl phos-
phate and inactive with β-glycerophosphate, glucose-
6-phosphate, carbamoylphosphate, creatine phosphate,
and tetrasodium pyrophosphate (Höglund and Reichard,
1990).
5#-nucleotidases influence the input of nucleotides
into the cellular pools by reversing the reaction cata-
lyzed by nucleoside kinases. The two deoxyribonucleo-
tidases, cdN and mdN, have been shown to modulate
the phosphorylation of thymidine and deoxyuridine by
creating regulatory substrate cycles with the cytosolic
(Bradshaw and Deininger, 1984) and mitochondrial (Jo-
hansson and Karlsson, 1997) thymidine kinases, re-
spectively (Gazziola et al., 2001; Rampazzo et al., 2004).
The physiological function of 5#-nucleotidases is how-
ever still incompletely clarified. A role in the catabolism
of macromolecular nucleic acids is recognized for cN-
III, a pyrimidine-specific 5#-nucleotidase specifically
expressed in red blood cells (Marinaki et al., 2001; Bi-
anchi and Spychala, 2003). A similar function may be
performed by other 5#-nucleotidases in other cell types.
5#-nucleotidases participate in the metabolism of nu-
cleoside analog drugs. Many antiviral and anticancer
nucleoside analogs are activated by phosphorylation to
their 5#-triphosphates and are then incorporated into
the DNA of the tumor cell or virus, where they primarily
act as DNA chain terminators. Nucleoside and nucleo-
tide kinases and 5#-nucleotidases control the level of
phosphorylation of the nucleoside analogs (Wang et al.,
1999; Mazzon et al., 2003; Van Rompay et al., 2003) and
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cleoside kinases and deoxyribonucleotidases show a
wide range of activities with different nucleoside ana-
logs (Wang et al., 1999; Mazzon et al., 2003; Van Rom-
pay et al., 2003). To be effective, a nucleoside analog
should be a good substrate for the kinases and be de-
phosphorylated poorly by the 5#-nucleotidases.
Several anti-HIV nucleoside analogs, e.g., 3#-azido
3#-thymidine (AZT) and 3#-deoxy 2#3#-didehydrothy-
midine (d4T), show mitochondrial toxicity (Lewis and
Dalakas, 1995) generally attributed to incorporation of
the analogs into mtDNA, which leads to DNA damage
and mtDNA depletion (Tozser, 2001). In fact, the tri-
phosphate form of anti-HIV nucleoside analogs such as
AZT and d4T can be incorporated into mtDNA by DNA
polymerase γ (Feng et al., 2001; Johnson et al., 2001;
Lim and Copeland, 2001). Overexpression of the inner
membrane nucleoside transporter ENT1 leads to an in-
creased incorporation of antiviral nucleoside analogs
into mtDNA (Lai et al., 2004). To reduce the mitochon-
drial toxicity of nucleoside analogs, the concentration
of their phosphates in mitochondria should be kept low.
This may possibly be accomplished by constructing
nucleoside analogs that are easily dephosphorylated
by mdN. The monophosphate form of AZT (AZTMP)
and d4T (d4TMP) are in fact dephosphorylated poorly
by mdN (Mazzon et al., 2003).
The structure of mdN (Rinaldo-Matthis et al., 2002) F
dwas the first structure determined of a mammalian 5#-
tnucleotidase, and it was determined with inorganic
(
phosphate in the active site and also with the product
thymidine trapped together with beryllium trifluoride
(BeF3−) (Rinaldo-Matthis et al., 2002). Thymidine binds o
with the 3#-hydroxyl group toward the BeF3−, indicating M
that the corresponding substrate would be dTMP3#.
t
The catalytic mechanism of mdN was outlined, and
pseveral relevant amino acids, water molecules, and co-
sfactors for substrate recognition were identified (Ri-
inaldo-Matthis et al., 2002).
cThe aim of the present study was to further investi-
gate the structural basis for substrate specificity of
(mdN by (1) looking at the difference in binding of sub-
cstrates phosphorylated at the 2#-, 3#-, and 5#-position
Aof the ribose and (2) comparing the binding of various
tnucleoside 5#-monophosphates. To achieve our aims, we
sused site-directed mutagenesis to produce an inactive
pmdN variant, D41N, in which substrates are bound but
mnot dephosphorylated. Here, we present seven structures
iof the D41N variant in complex with the nucleoside mo-
snophosphates dTMP5#, dTMP3#, dUMP5#, dGMP5#, uri-
gdine 2#-monophosphate (UMP2#); uridine 5#-monophos-
tphate (UMP5#); and d4TMP. By combining the new
astructural information of substrate binding with activity
smeasurements, we have been able to provide a struc-
atural explanation of why mdN prefers 2#-deoxyribo-
4nucleoside over ribonucleoside 5#-monophosphates
Tand why it shows low activity for dGMP5#. The new
information about substrate binding could potentially
pbe used in the design of novel anti-HIV nucleoside ana-
slogs with reduced mitochondrial toxicity.
U
pResults and Discussion
o
nThe D41N variant of mdN was prepared with the pur-pose of trapping various substrates in the active sitef mdN. In the reaction mechanism of mdN (Rinaldo-
atthis et al., 2002), Asp-41 makes a nucleophilic at-
ack on the phosphate moiety of the nucleoside mono-
hosphate. In the D41N variant, residue Asp-41 is
ubstituted by the poor nucleophile asparagine, which
nstead forms hydrogen bonds to the substrate, effi-
iently trapping it in the active site.
Similar to the previously published mdN structures
Rinaldo-Matthis et al., 2002), the present structures
ontain 194 out of 197 residues (amino acids 34–227).
mino acids 1–31 constitute the mitochondrial localiza-
ion signal and were not part of the expressed con-
truct. It is a homodimer, and each monomer is com-
osed of a large and a small domain. The active site of
dN is found in a cleft between the two domains and
s solvent accessible. All present and previously solved
tructures contain a Mg2+ ion, to which either the inor-
anic phosphate, the phosphate moiety of the nucleo-
ide, BeF3−, or AlF4− is coordinated (Rinaldo-Matthis et
l., 2002; Rinaldo-Matthis, 2004). Many residues con-
erved between the known 5#-nucleotidases are situ-
ted around the phosphate binding site. These are Asp-
1 (Asn-41), Asp-43, Lys-165, Asp-175, Asp-176, and
hr-130.
The electron density of the substrate is readily inter-
reted already in the initial Fo-Fc map, for all seven
tructures (Figure 1). In the structures with dUMP5# and
MP5#, the density of the ribose and especially of the
hosphate moiety is divided approximately equally
ver two locations, indicating the presence of two alter-
ative conformations (Figure 1). Here, we describeigure 1. Electron Density and Bound Substrates
UMP5# and UMP5# are modeled with the two alternate conforma-
ions superimposed. The OMIT maps are generated in Refmac5
Murshudov et al., 1997).these as two different phosphate binding modes, Mode
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1083Figure 2. Schematic Diagrams of the Active Site of D41N
Top: Mode A, shown by the phosphate binding of dTMP3#. Bottom:
Mode B, shown by the phosphate binding of dTMP5#. Waters are
marked as “W.”A and Mode B (Figure 2). dTMP3# and UMP2# bind only
with Mode A, dTMP5# and d4TMP bind only with Mode
B, and dGMP5# is somewhat displaced from the phos-
phate binding site (see below).
The location of the phosphate in Mode A (Figure 2,
top) is very similar to that of inorganic phosphate in a
previously determined structure of wild-type mdN (Ri-
naldo-Matthis et al., 2002). The oxygen connecting the
phosphate with the nucleoside (O5#) is within hydrogen
bonding distance to Asp-43, a catalytically important
residue that donates a proton to the leaving nucleoside
product (Rinaldo-Matthis et al., 2002). The phosphate
also makes hydrogen bonds to the amine group of Asn-
41, the hydroxyl group of Thr-130, the main chain amide
of Ser-131, and to several water molecules (WB, WC,
and WD). The phosphate is also coordinated to the
Mg2+ ion. These interactions are similar to those be-
tween the wild-type mdN and inorganic phosphate/
BeF3− described previously (Rinaldo-Matthis et al.,
2002). However, Lys-165, which previously has been
seen to coordinate to phosphate and BeF3−, is not mak-
ing an interaction to the phosphate moiety in Mode A.
A likely explanation for this could be that, since the
negative charge of Asp-41 is removed in D41N, a close
coordination of Lys-165 to the phosphate moiety would
create an unfavorable charge distribution. It is likely
that the D41N mutation has created a situation in whichthe conserved Lys-165 is not stabilizing the productive
phosphate binding mode for catalysis, as has been
suggested for wild-type mdN (Rinaldo-Matthis et al.,
2002).
Mode B (Figure 2, bottom) shows a phosphate that
“has rotated” around the C4#-C5# bond of the ribose.
We believe that Mode B is an artifact of the mutation,
due to the changed charge distribution, and is not a
biologically relevant situation. In Mode B, the O5# is not
within hydrogen bonding distance to Asp-43 or to any
other possible proton donor, which indicates that this
binding mode is nonproductive. Here, the phosphate
makes a hydrogen bond to Lys-165. The phosphate
moiety is not within hydrogen bonding distance to Thr-
130, but it is coordinated to the Mg2+ ion and makes
hydrogen bonds to the amine group of Asn-41 and to
the main chain of Ser-131, as well as to several water
molecules (WB, WC, WE, and WF). A water molecule (WE)
is situated between Asp-43 and the phosphate moiety
within hydrogen bonding distance to Asp-43, but not
to O5#. WF connects the phosphate to Arg-177 (Figure
2, bottom).
In D41N, it is possible that the protonation state of
Asp-43 determines whether the phosphate moiety will
make a hydrogen bond to Asp-43 (Mode A) or to Lys-
165 (Mode B). It is likely that the carboxyl group of Asp-
43 is protonated in Mode A, where it makes a hydrogen
bond to O5#, and is deprotonated in Mode B, where it
repels the O5# (Figure 2). It is evident from the present
structures that several of the substrates can display
both binding modes. The difference in phosphate bind-
ing could depend on the fact that the pKa values of the
phosphate and Asp-43 are close to the pH of the crystal
soaking solutions.
Since Mode A is almost identical to the binding of
inorganic phosphate in wild-type mdN, and the sugar/
base binding of dTMP3# is almost identical to the bind-
ing of thymidine in wild-type mdN (Figure 3A) (Rinaldo-
Matthis et al., 2002), the structures with Mode A most
likely picture substrate binding very closely to how it
actually occurs in vivo. The structure with dTMP3# also
verifies the conclusions previously drawn about sub-
strate binding and the catalytic mechanism of the en-
zyme (Rinaldo-Matthis et al., 2002). Even though Mode
B most likely is an artifact due to the changed charge
distribution, the structures with Mode B are also rele-
vant for understanding sugar and base binding, since
only small changes in the conformation of the sugar
moiety occur and almost no detectable conformational
changes of the base are present (Figure 1).
Nucleoside 2-, 3-, and 5-Monophosphate Binding
A comparison of the binding of UMP2#, dTMP3#, and
dUMP5# (Figures 3B and 3C) shows that the ribose and
base of dUMP5# are rotated relative to UMP2# and
dTMP3#. Here, dUMP5# is representative also of UMP5#,
dTMP5#, and d4TMP, since their base moieties bind
very similarly and their ribose moieties bind relatively
similarly (the differences in ribose binding between the
nucleoside 5#-monophosphates will be discussed
below).
The bases of dTMP3# and UMP2# bind almost iden-
tically and make only one direct hydrogen bond to the
protein, which is between the O4 atom of the thymine/
Structure
1084Figure 3. The Binding of UMP2#, dTMP3#,
and dUMP5#
(A) Comparison of the binding of substrate,
product, and inorganic phosphate. The sub-
strate dTMP3# is superimposed on the pre-
viously determined structures with the prod-
uct thymidine together with BeF3−, and the
native structure is superimposed with inor-
ganic phosphate (Rinaldo-Matthis et al.,
2002). dTMP3# is shown in green, thymidine
is shown in light gray, BeF3− is shown in light
gray and indigo, and inorganic phosphate is
shown in blue.
(B) Comparison of the base binding of
dTMP3# and dUMP5# (Mode A), in stereo.
The structures with dTMP3# (green) and
dUMP5# (violet) are superimposed.
(C) A stereo view comparing the ribose bind-
ing of dTMP3# and UMP2#. The structure
with dTMP3# (green) is superimposed on the
structures with UMP2# (yellow) and dUMP5#
(Mode A, transparent). No amino acid resi-
dues are shown from the structure with
dUMP5#.
(D) Stereo view of the structure with dUMP5#,
showing the two alternative conformations of
dUMP5#. dUMP5# (Mode A) is shown in violet,
and dUMP5# (Mode B) is shown in dark violet.uracil ring and the amide group of Val-77. The thymine/ P
muracil ring makes several interactions with water mole-
cules that mediate contact with the Mg2+ ion and the 7
protein (Figure 3B). The thymine ring of dTMP3# (and
the uracil ring of UMP2#) is stacked parallel to Phe-49 d
iwith a distance of 3.4 Å. It is also stacked parallel byhe-75 (3.9 Å), and the 5-methyl group of thymine
akes van der Waals interactions of 3.5 Å to both Trp-
6 and Trp-96 (Figure 3B).
The O4 atom of the uracil ring of dUMP5# makes hy-
rogen bonds to the amide group of Val-77, to the am-
de group of Ser-78, and to a water molecule that medi-
Structures of Mitochondrial Deoxyribonucleotidase
1085Table 1. Relative Activity of mdN and Kinetic Parameters
Substrate Relative Activitya Km (mM) Vmax (Units/mg) Vmax/Km
dUMP5# 100 0.16 145 909
UMP5# 30 0.14 46 323
UMP2# 18 0.05 30 600
dTMP5# 50 0.3 77 270
dTMP3# 77 0.17 144 833
dGMP5# 6 0.09 15 167
d4TMP5#b 9 0.3 14 47
a Values are taken from a previous publication (Rampazzo et al., 2000a) and were measured at pH 5.5 with a substrate concentration of 2 mM.
b Values are taken from a previous publication (Mazzon et al., 2003) and were measured at pH 7.5 with a substrate concentration of 2 mM.the glycerol molecule is not affecting the binding mode 1); (2) the stacking interactions of both dTMP3# and
Figure 4. Comparisons of the Binding of Dif-
ferent Nucleoside 5#-Monophosphates
(A) Superposition of the structure with
dGMP5# (blue) and the structure with the two
alternative conformations of dUMP5# (trans-
parent), in stereo.
(B) Superposition of the structures with
dUMP5# (purple) and UMP5# (yellow).
(C) Superposition of the structures with
dTMP5# (light gray) and d4TMP5# (orange).ates interaction with the side chain of Ser-78 (Figure
3B). The uracil ring of dUMP5# is stacked by Phe-49,
Phe-75, Trp-76, and Trp-96, but to a lesser extent than
the pyrimidine bases in dTMP3# and UMP2#. The uracil
ring is closer to Trp-76 and Trp-96 than to Phe-49,
which is more than 4 Å away and is not stacked parallel
to it. The N3 of the uracil ring of dUMP5# is relatively
close to non-polar parts of the two tryptophans. Phe-
75 and Trp-76 have moved slightly relative to their posi-
tions in the structure with dTMP3# (Figure 3B). The resi-
dues Phe-49, Phe-75, Trp-76, and Trp-96 form a pocket,
which fits dTMP3# very well, but fits the dUMP5# (and
all nucleoside 5#-monophosphates included in this
study) less well.
One glycerol molecule that probably originates from
the cryosolution used for freezing the protein crystals
is found in the active site of the structure with dUMP5#,
where it coordinates the Mg2+ ion (Glc in Figure 3B).
None of the other structures included in this paper have
glycerol bound at this position, and since the binding
mode of dUMP5# is so similar to the binding modes of
UMP5#, dTMP5#, and d4TMP, it is most probable thatof the substrates but rather fills positions normally oc-
cupied by water molecules.
The sugar moieties of dTMP3# and UMP2# bind to
water molecules that mediate interaction with the pro-
tein (Figure 3C). The nucleoside 5#-monophosphates
bind with two different sugar ring conformations, in
which the 3#-hydroxyl group interacts with the enzyme
in two different ways (Figure 3D): (1) In dUMP5# (Mode
A), UMP5# (Mode A), and dTMP5#, the 3#-hydroxyl
group makes hydrogen bonds to the main chain car-
bonyl group of Ser-131 and the main chain amide group
of Ile-133. (2) In dGMP5#, dUMP5# (Mode B), and
UMP5# (Mode B), it makes hydrogen bonds to the side
chain carboxyl group of Asp-43 and to a water mole-
cule. In both binding modes, the hydroxyl group makes
direct interactions with the protein, leaving limited
space for a putative bulky substituent, e.g., the azido
group of the nucleoside analog AZT.
Four factors support the idea that not only nucleo-
side 5#-monophosphates, but also nucleoside 3#-
monophosphates, are biologically relevant substrates.
These are: (1) mdN has high activity for dTMP3# (Table
Structure
1086Table 2. Crystallographic Data Collection and Refinement Statistics
Data Collection
Parameters Substrate
dTMP3# dTMP5# dUMP5# UMP5# UMP2# dGMP5# d4TMP5#
Space group P43212 P43212 P43212 P43212 P43212 P43212 P43212
Unit Cell Dimensions (Å)
a = b 73.18 73.65 73.7 73.57 73.45 73.38 73.77
c 105.92 106.38 106.42 105.75 106.09 105.437 106.06
Data Collection Statistics
Resolution (Å) 20–1.75 40–1.8 20–2.0 40–1.7 37–1.8 40–2.00 20–2.05
I/σ(I)a 15.9 (5.2) 17.7 (3.9) 23.6 (7.8) 24.5 (3.7) 27.3 (4.7) 25.5 (4.5) 21.5 (4.3)
Number of unique 29,986 27,554 20,833 32,144 27,294 20,174 18,971
reflections
Redundancy of 7.5 4.9 15.1 5.0 8.2 6.6 6.1
reflections
Rsyma,b 7.2 (32) 5.6 (35) 8.0 (36) 4.7 (33.4) 6.1 (37) 7.2 (45) 7.3 (37)
Completeness (%)a 92.7 (95.0) 99.4 (99.4) 99.8 (100) 98.5 (98.3) 98.4 (98.8) 99.6 (99.9) 99.7 (100)
Final Refinement Parameters
Rwork valuec 17 17 16 19 17 19 17
Number of reflections, 26,334 26,283 19,762 30,463 25,876 19,103 17,970
working set
Rfree valuec 18 21 20.6 21 20 21.5 21
Number of reflections, 1,420 1,383 1,069 1,624 1,369 1,027 976
test set
Mean B factors (Å2) 22.3 19.3 26.5 24.3 20.8 22.9 25.2
Residues in most 92.9 92.9 92.4 91.8 92.9 91.8 92.4
favorable regions (%)d
Residues in additionally 7.1 7.1 7.6 8.2 7.1 8.2 7.6
allowed regions (%)d
Rmsd bond length (Å) 0.018 0.019 0.019 0.015 0.018 0.019 0.02
Rmsd bond angles (°) 1.682 1.790 1.690 1.631 1.755 1.684 1.672
PDB code 1Z4K 1Z4L 1Z4I 1Z4M 1Z4J 1Z4P 1Z4Q
a Numbers in parentheses are for the highest resolution shell.
b Rsym = (ShklSirIi(hkl) − <I(hkl)>r)/ShklSiIi(hkl) for n independent reflections and observations of a given reflection; <I(hkl)> is the average
intensity of the ith observation.
c Rcryst = ShklrF0(hkl) − Fc(hkl)r/ShrF0(hkl)r.
d Ramachandran plots are made by using PROCHECK Validation (Laskowski et al., 1993).UMP2# are more favorable than those of the nucleoside A
5#-monophosphates; (3) the two stacking phenylala- n
nines (Phe-49 and Phe-75) are conserved between m
mdN and cdN, which indicates the biological impor- o
tance of this stacking; and (4) in the previously solved C
structure of mdN in complex with the nucleoside prod- p
uct, the 3#-hydroxyl group of the nucleoside product c
is pointing toward the phosphate binding site, which p
indicates that the enzyme has higher affinity for nucleo-
side 3#-monophosphates than for nucleoside 5#-mono- d
phosphates. a
r
7Nucleoside 5-Monophosphate Specificity
gPurine/Pyrimidine Specificity
wThe activity of mdN is much lower with purine nucleo-
ttides, e.g., dGMP5#, than with the pyrimidine sub-
mstrates dTMP5# and dUMP5# (Table 1). The difference
dis especially marked at saturating substrate concentra-
Dtions. The structure of mdN with bound dGMP5# reveals
Tthat dGMP5# is displaced 1 Å relative to the other nucleo-
rside 5#-monophosphates, which causes a longer distance
l(4.4 Å) between O5# and the catalytically important Asp-
f43 (Figure 4A) than in the other substrate-D41N com-
dplexes that display Mode A. This longer distance to
Asp-43 probably makes the transfer of a proton from (sp-43 to the leaving nucleoside in the reaction mecha-
ism less efficient, and thus causes the low activity of
dN with dGMP5#. The phosphate moiety of dGMP5#
verlaps with that of Mode B, but a rotation around the
5#-O5# bond of the nucleotide would not place the
hosphate in a location similar to Mode A, since the lo-
ation of the sugar ring and the rest of the nucleotide
rohibits the phosphate moiety from reaching Mode A.
The O6 of the guanine ring of dGMP5# makes hy-
rogen bonds to the amide of Val-77 and to the amide
nd hydroxyl groups of Ser-78. The N7 of the guanine
ing makes a hydrogen bond to the amide group of Val-
7, and the O4# of the ribose moiety and the amide
roup of the guanine ring make hydrogen bonds to
ater molecules (Figure 4A). It is probable that the in-
eractions with Val-77 and Ser-78 cause the displace-
ent of dGMP5#, and thus the preference for pyrimi-
ines over purines.
eoxyribo/Ribo Specificity
he deoxyribonucleotidase mdN prefers the 2#-deoxy-
ibo form of nucleoside 5#-monophosphates and shows
ower catalytic efficiency with the corresponding ribo
orm, e.g., UMP5# (Table 1). The substrates UMP5# and
UMP5# bind remarkably similarly in the D41N variant
Figure 4B). However, the 2#-hydroxyl group of UMP5#
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from Phe-49, 3.5 Å from Phe-102, and 2.6 Å from Ile-
133, all energetically unfavorable interactions. For
dUMP5#, on the other hand, these hydrophobic resi-
dues constitute a favorable surface for interactions with
the 2#-carbon, which suggests that dUMP5# is bound
with higher affinity than UMP5#. However, judging from
the kinetic parameters for these two substrates in Table
1, this difference in the interactions with the enzyme
affects the Vmax, but not the Kms, which are the same
for dUMP5# and UMP5#.
Importance of the 3#-Hydroxyl Group of dNMP5’s
The 5#-monophosphate of the anti-HIV thymidine ana-
log d4T (d4TMP) is a poor substrate for mdN (Table 1).
d4TMP lacks the 3#-hydroxyl group that is present in
dTMP5# and has a double bond between the C2# and
C3# atoms. Even though the double bond makes the
conformation limited to O4-endo envelope puckering,
the sugar ring still occupies similar space as the sugar
ring of dTMP5#. The 3#-carbons of d4TMP and dTMP5#
are in a similar position and the bases bind almost iden-
tically. The only detectable difference in the interactions
with the enzyme is that dTMP5# has two additional hy-
drogen bonds: the hydrogen bonds between the 3#-hy-
droxyl group and the carbonyl group of Ser-131 and the
amide group of Ile-133. These hydrogen bonds are
most likely more favorable than the exposure of the 3#-
carbon of d4TMP to this polar environment, which is in
agreement with the difference in relative activity be-
tween the two substrates (Table 1). The lack of a polar
group at the 3# position of the sugar would probably
in general destabilize the binding in mdN, causing a
lower Vmax.
Nucleoside Analog Specificity
The binding of the nucleoside 5#-monophosphates re-
veals that the parts of the base that are not involved in
direct interactions with the protein are surrounded by
water molecules, which could potentially be substi-
tuted by other solvent molecules (e.g., glycerol; Figure
3B) or by a functional group of a nucleoside analog.
The structures with UMP5# and d4TMP indicate that a
nucleoside analog should have a small polar or charged
group at the 3# position of the ribose and have no polar
or charged functional group at the 2# position of the
ribose, in order to maintain activity.
Possibly, a nucleoside analog that is substituted on
the base (with the exception of the O4 position) is more
likely to be a good substrate for mdN than one substi-
tuted on the ribose.
Experimental Procedures
Site-Directed Mutagenesis
Site-directed mutagenesis of mdN was performed as described by
Sambrook and Russel (2001). We used two complementary oligo-
nucleotides to introduce the mutation: 5#-gccgtccatgttcacca
gcaccc-3# and 5#-gggtgctggtgaacatggacggc-3# (small letters indi-
cate wild-type bases; bold letters indicate mutated bases). As ex-
ternal primers we used 5#-catacatatgggaggccgcgccctacg-3# and
5#-ctgaggatccagccccacagagga-3#, which introduce a 5# NdeI and
a 3# BamHI site, respectively (underlined). After PCR amplification,
the mutated cDNA lacking the codons for the 31 N-terminal amino
acids with the mitochondrial targeting signal was cloned into
pET20 vector (Novagen, Madison, WI, USA). The recombinant plas-
mid, called pET20-D41NmdN, was sequenced to confirm the pres-
ence of the mutation.Protein Expression and Purification
Plasmid pET20-D41NmdN was transformed into Escherichia coli
BL21(DE3) plysS . The bacterial culture (9 L) was grown at 37°C in
LB medium to an OD600 of 0.5–0.6 and was induced with 0.4 mM
isopropyl-β-D-thiogalactoside for 3 hr. Extracts were prepared as
described previously (Rampazzo et al., 2000b), and the D41N vari-
ant of mdN was purified by following the same procedure as that
used previously for wild-type mdN (Rampazzo et al., 2000a). Briefly,
the enzyme was purified by ammonium sulfate fractionation, chro-
matographed on a DE52 column (Whatman) with a 0–150 mM NaCl
gradient in buffer A (20 mM Tris-HCl [pH 7.5], 1 mM EDTA [pH 7.6],
2 mM DTT, and 20% [v/v] glycerol). The peak was rechromato-
graphed on a Phenyl Sepharose CL-4B column (Amersham Phar-
macia) with a 1.5–0 M gradient of ammonium sulfate in buffer A.
The peak was loaded again in a desalting biogel column (BioRad)
in order to remove ammonium sulfate.
Enzyme Assays
Dephosphorylation of nucleotides was measured with a sensitive
colorimetric assay from the formation of inorganic phosphate (Gel-
adopoulos et al., 1991). Incubations were at 37°C for 30 min with
substrate, 10 mM Mg2+, 30 mM KCl, and 250 mM acetate buffer
(pH 5.5) in a final volume of 50 l. The reaction was stopped by
the addition of 1/8 volume H2SO4 (1.1 M), and, after centrifugation,
inorganic phosphate was determined. One unit of enzyme activity
corresponds to the dephosphorylation of 1 mol substrate per min-
ute. Specific activity is units per mg protein. Km and Vmax values
were obtained from the extrapolated maximal specific activity of
the Lineweaver-Burk plots. All experiments were done in triplicate
at different concentrations of the substrate and were repeated at
least three times. In all kinetic experiments, care was taken not to
consume more than 25% of the substrate during the reaction.
Crystallization, Soaking Experiments, and Cryoprotection
The D41N variant of mdN was crystallized under the same condi-
tions as those described for mdN (Rinaldo-Matthis et al., 2002). The
protein solution used for crystallization contained 20 mM Tris buffer
(pH 7.5), 20% (v/v) glycerol, 2 mM DTT, 1 mM EDTA, 75 mM NaCl,
and 10.1 mg ml−1 protein. Crystals were obtained by using the
hanging drop vapor diffusion method with 1 l protein solution and
1 l reservoir solution at 20°C. The reservoir solution contained
15%–20% (w/v) PEG 8000 and 50 mM KH2PO4 (pH 4.5). Crystals
appeared after 1 day and reached a maximum size of 0.2 × 0.2 ×
0.3 mm. The D41N crystals were soaked in 10 l drops containing
10 mM nucleoside monophosphate, 90 mM MgCl2, 50 mM sodium
acetate (pH 4.5), and 20% (w/v) PEG 8000 for 1–2 hr. The pH of the
nucleoside monophosphate solutions was adjusted to pH 5 prior
to soaking. The crystals were then transferred to a 10 l drop of
cryosolution containing 20% (w/v) PEG 8000, 50 mM sodium ace-
tate (pH 4.5), and 20% (v/v) glycerol for 20–60 s and subsequently
flash frozen in liquid N2. For the structure with dGMP5#, 20% PEG
400 (v/v) was used instead of glycerol in the cryosolution.
Data Collection, Structure Determination, and Refinement
The data sets of D41N in complex with dTMP3# and dUMP5# were
collected at the European Synchrotron Radiation Facility (ESRF) at
the beamline ID14.3, the data set of D41N in complex with dGMP5#
was collected at the Protein Structure Factory-Berliner Elektronen-
speicherring-Gesellschaft für Synchrotron Strahlung m. b. H. (PSF-
BESSY) at beamline BL1, and the data sets of D41N in complex
with UMP5#, UMP2#, dTMP5#, and d4TMP were collected at The
European Molecular Biology Laboratory (EMBL) Hamburg Outsta-
tion at the beamline X11. The data sets with dTMP3# and dUMP5#
were processed with XDS and XSCALE (Kabsch, 1988); the other
data sets were processed by using the program package DENZO/
SCALEPACK (Otwinowski and Minor, 1997). The crystals belong to
the space group P43212, with one polypeptide per asymmetric unit.
Refmac5 (Murshudov et al., 1997) was used for structure deter-
mination and refinement, and the previously determined mdN
structure (Rinaldo-Matthis et al., 2002) was used as a template for
the initial Rigid Body refinement of the seven data sets. Quanta
(Accelrys, San Diego, CA) was used for model building, and X-SOL-
Structure
1088VATE (Accelrys) was used for the addition of waters. Structural sta- M
stistics are shown in Table 2.
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